FDA Lifts Clinical Holds On Anemia Compounds Under Development By Astellas/FibroGen
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approves protocols proposed by FibroGen to resume Phase II trials of FG-2216 and FG-4592.
You may also be interested in...
AstraZeneca’s “Smart Risks” Include Sharing FibroGen’s Anemia Compound With Astellas
The British pharma continues to build its cardiovascular and metabolic pipeline to slow its dive off the patent cliff; in FibroGen’s FG-4592, it sees a potential strong seller in regions where the privately held biotech's other pharma partner, Astellas, doesn’t already own rights.
Affymax, Takeda Report Positive Phase II Data On Anemia Candidate
Hematide maintained mean hemoglobin levels for up to 18 months in patients previously treated with epoetin alfa, the companies report.
Affymax, Takeda Report Positive Phase II Data On Anemia Candidate
Hematide maintained mean hemoglobin levels for up to 18 months in patients previously treated with epoetin alfa, the companies report.